Lanctot KL - Search Results

1

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.

Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA; CARESS investigators. Mitchell I, et al. Among authors: lanctot kl. Am J Perinatol. 2022 Nov;39(15):1668-1677. doi: 10.1055/s-0041-1725146. Epub 2021 Mar 3. Am J Perinatol. 2022. PMID: 33657636 Free PMC article.

2

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.

Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators. Oh PI, et al. Among authors: lanctot kl. Pediatr Infect Dis J. 2002 Jun;21(6):512-8. doi: 10.1097/00006454-200206000-00007. Pediatr Infect Dis J. 2002. PMID: 12182374 Clinical Trial.

3

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI. Lanctôt KL, et al. Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234. Epub 2008 Oct 16. Curr Med Res Opin. 2008. PMID: 18928643

4

Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.

Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, Roberts A. Banerji A, et al. Among authors: lanctot kl. Pediatr Infect Dis J. 2009 Aug;28(8):702-6. doi: 10.1097/INF.0b013e31819df78e. Pediatr Infect Dis J. 2009. PMID: 19461555

5

The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic.

Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctôt KL. Tam DY, et al. Among authors: lanctot kl. J Med Econ. 2009;12(4):361-70. doi: 10.3111/13696990903442155. J Med Econ. 2009. PMID: 19900071 Free article.

6

The cost effectiveness of palivizumab: a systematic review of the evidence.

Smart KA, Lanctôt KL, Paes BA. Smart KA, et al. Among authors: lanctot kl. J Med Econ. 2010;13(3):453-63. doi: 10.3111/13696998.2010.499749. J Med Econ. 2010. PMID: 20653398 Free article. Review.

7

Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts.

Herrmann N, Black SE, Li A, Lanctôt KL. Herrmann N, et al. Among authors: lanctot kl. Int Psychogeriatr. 2011 May;23(4):539-45. doi: 10.1017/S1041610210001535. Epub 2010 Sep 20. Int Psychogeriatr. 2011. PMID: 20849673 Clinical Trial.

8

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Smart KA, Lanctôt KL, Paes BA. Smart KA, et al. Among authors: lanctot kl. Can Fam Physician. 2010 Oct;56(10):988-91. Can Fam Physician. 2010. PMID: 20944037 Free PMC article. No abstract available.

9

Changing costs and the impact on RSV prophylaxis.

Smart KA, Paes BA, Lanctôt KL. Smart KA, et al. Among authors: lanctot kl. J Med Econ. 2010;13(4):705-8. doi: 10.3111/13696998.2010.535577. Epub 2010 Nov 18. J Med Econ. 2010. PMID: 21087075 Free article.

10

CARESS: the Canadian registry of palivizumab.

Mitchell I, Paes BA, Li A, Lanctôt KL; CARESS investigators. Mitchell I, et al. Among authors: lanctot kl. Pediatr Infect Dis J. 2011 Aug;30(8):651-5. doi: 10.1097/INF.0b013e31821146f7. Pediatr Infect Dis J. 2011. PMID: 21343842

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters